Structural and energetic analyses of SNPs in drug targets and implications for drug therapy

Journal of Chemical Information and Modeling

Volumn 53, Issue 12, 2013, Pages 3343-3351

  Sun, Hui Yong ^a,b   Ji, Feng Qin ^a   Fu, Liang Yu ^a   Wang, Zhong Yi ^a   Zhang, Hong Yu ^a  

^a HUAZHONG AGRICULTURAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; BINDING SITES; DISEASE CONTROL;

CHEMICAL TREATMENTS; DRUG BINDING SITES; ENERGETIC ANALYSIS; ENERGY PROPERTY; GENETIC DISEASE; SINGLE NUCLEOTIDE POLYMORPHISMS; THERAPEUTIC EFFECTS; THERAPEUTIC TARGETS;

DRUG THERAPY;

PRESCRIPTION DRUG; PROTEIN;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG POTENTIATION; GENETIC DATABASE; GENETIC SELECTION; GENETICS; HAPLOTYPE MAP; HUMAN; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; MUTATION; SINGLE NUCLEOTIDE POLYMORPHISM; THERMODYNAMICS;

DATABASES, GENETIC; HAPMAP PROJECT; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; MOLECULAR TARGETED THERAPY; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PRESCRIPTION DRUGS; PROTEINS; SELECTION, GENETIC; THERMODYNAMICS;

EID: 84896534505     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci400457v     Document Type: Article

References (71)

1. Gorre, M. E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P. N.; Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 2001, 293, 876-880
2. Yun, C.-H.; Mengwasser, K. E.; Toms, A. V.; Woo, M. S.; Greulich, H.; Wong, K.-K.; Meyerson, M.; Eck, M. J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 2070-2075
3. Choi, Y. L.; Soda, M.; Yamashita, Y.; Ueno, T.; Takashima, J.; Nakajima, T.; Yatabe, Y.; Takeuchi, K.; Hamada, T.; Haruta, H. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors N. Engl. J. Med. 2010, 363, 1734-1739
4. Sun, H. Y.; Ji, F. Q. A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK Biochem. Biophys. Res. Commun. 2012, 423, 319-324
5. Sun, H.; Li, Y.; Li, D.; Hou, T. Insight into crizotinib resistance mechanisms caused by three mutations in ALK tyrosine kinase using free energy calculation approaches J. Chem. Inf. Model. 2013, 53, 2376-2389
6. Karczewski, K. J.; Daneshjou, R.; Altman, R. B. Chapter 7: Pharmacogenomics PLoS Comput. Biol. 2012, 8, e1002817
7. Kell, D. B.; Dobson, P. D.; Bilsland, E.; Oliver, S. G. The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: What we (need to) know and how we can do so Drug Discovery Today 2013, 18, 218-239
8. Sachidanandam, R.; Weissman, D.; Schmidt, S. C.; Kakol, J. M.; Stein, L. D.; Marth, G.; Sherry, S.; Mullikin, J. C.; Mortimore, B. J.; Willey, D. L. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms Nature 2001, 409, 928-933
9. Wood, A. J. J.; Evans, W. E.; McLeod, H. L. Pharmacogenomics-Drug disposition, drug targets, and side effects N. Engl. J. Med. 2003, 348, 538-549
10. Zhu, F.; Shi, Z.; Qin, C.; Tao, L.; Liu, X.; Xu, F.; Zhang, L.; Song, Y.; Zhang, J. Therapeutic target database update 2012: A resource for facilitating target-oriented drug discovery Nucleic Acids. Res. 2012, 40, 1128-1136
11. Sayers, E. W.; Barrett, T.; Benson, D. A.; Bolton, E.; Bryant, S. H.; Canese, K.; Chetvernin, V.; Church, D. M.; DiCuccio, M.; Federhen, S. Database resources of the national center for biotechnology information Nucleic Acids. Res. 2011, 39, 38-51
12. Apweiler, R.; Martin, M.; O'Donovan, C.; Magrane, M.; Alam-Faruque, Y.; Antunes, R.; Barrell, D.; Bely, B.; Bingley, M.; Binns, D. The universal protein resource (UniProt) in 2010 Nucleic Acids. Res. 2010, 38, 142-148
13. Gibbs, R. A.; Belmont, J. W.; Hardenbol, P.; Willis, T. D.; Yu, F.; Yang, H.; Ch'ang, L. Y.; Huang, W.; Liu, B.; Shen, Y. The international HapMap project Nature 2003, 426, 789-796
14. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility J. Comput. Chem. 2009, 30, 2785-2791
15. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function J. Comput. Chem. 1998, 19, 1639-1662
16. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges Tetrahedron 1980, 36, 3219-3228
17. Frisch, M.; Trucks, G.; Schlegel, H.; Scuseria, G.; Robb, M.; Cheeseman, J.; Montgomery, Jr, J.; Vreven, T.; Kudin, K.; Burant, J. Gaussian 03; Gaussian, Inc.: Wallingford, CT, 2004.
18. Bayly, C. I.; Cieplak, P.; Cornell, W.; Kollman, P. A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: The RESP model J. Phys. Chem. 1993, 97, 10269-10280
19. Wang, J.; Cieplak, P.; Kollman, P. A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J. Comput. Chem. 2000, 21, 1049-1074
20. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field J. Comput. Chem. 2004, 25, 1157-1174
21. Dickson, C. J.; Rosso, L.; Betz, R. M.; Walker, R. C.; Gould, I. R. GAFFlipid: A General Amber Force Field for the accurate molecular dynamics simulation of phospholipid Soft Matter 2012, 8, 9617-9627
22. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 1983, 79, 926-935
23. Phillips, J. C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R. D.; Kale, L.; Schulten, K. Scalable molecular dynamics with NAMD J. Comput. Chem. 2005, 26, 1781-1802
24. Darden, T.; York, D.; Pedersen, L. Particle mesh Ewald: An N log(N) method for Ewald sums in large systems J. Chem. Phys. 1993, 98, 10089-10092
25. Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. J. C. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes J. Comput. Phys. 1977, 23, 327-341
26. Feller, S. E.; Zhang, Y.; Pastor, R. W.; Brooks, B. R. Constant-pressure molecular-dynamics simulation-the Langevin piston method J. Chem. Phys. 1995, 103, 4613-4621
27. Hou, T.; Li, N.; Li, Y.; Wang, W. Characterization of domain-peptide interaction interface: Prediction of SH3 domain-mediated protein-protein interaction network in yeast by generic structure-based models J. Proteome Res. 2012, 11, 2982-2995
28. Hou, T.; Li, Y.; Wang, W. Prediction of peptides binding to the PKA RIIα subunit using a hierarchical strategy Bioinformatics 2011, 27, 1814-1821
29. Hou, T.; Wang, J.; Li, Y.; Wang, W. Assessing the performance of the MM/PBSA and MM/GBSA methods: I. The accuracy of binding free energy calculations based on molecular dynamics simulations J. Chem. Inf. Model. 2011, 51, 69-82
30. Hou, T.; Wang, J.; Li, Y.; Wang, W. Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking J. Comput. Chem. 2011, 32, 866-877
31. Hou, T.; Yu, R. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance J. Med. Chem. 2007, 50, 1177-1188
32. Li, L.; Li, Y.; Zhang, L.; Hou, T. Theoretical studies on the susceptibility of oseltamivir against variants of 2009 A/H1N1 influenza neuraminidase J. Chem. Inf. Model. 2012, 52, 2715-2729
33. Xu, L.; Sun, H.; Li, Y.; Wang, J.; Hou, T. Assessing the performance of MM/PBSA and MM/GBSA methods. 3. The impact of force fields and ligand charge models J. Phys. Chem. B 2013, 117, 8408-8421
34. Xue, W.; Jin, X.; Ning, L.; Wang, M.; Liu, H.; Yao, X. Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis J. Chem. Inf. Model. 2013, 53, 210-222
35. Zhang, J.; Hou, T.; Wang, W.; Liu, J. S. Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 1321-1326
36. Onufriev, A.; Bashford, D.; Case, D. A. Exploring protein native states and large-scale conformational changes with a modified generalized born model Proteins: Struct., Funct., Bioinf. 2004, 55, 383-394
37. Weiser, J.; Shenkin, P. S.; Still, W. C. Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) J. Comput. Chem. 1999, 20, 217-230
38. Brooks, B.; Karplus, M. Harmonic dynamics of proteins: Normal modes and fluctuations in bovine pancreatic trypsin inhibitor Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 6571-6575
39. Genheden, S.; Kuhn, O.; Mikulskis, P.; Hoffmann, D.; Ryde, U. The normal-mode entropy in the MM/GBSA method: Effect of system truncation, buffer region, and dielectric constant J. Chem. Inf. Model. 2012, 52, 2079-2088
40. Miller, B. R., III; McGee, T. D.; Swails, J. M.; Homeyer, N.; Gohlke, H.; Roitberg, A. E. MMPBSA.py: An efficient program for end-state free energy calculations J. Chem. Theory Comput. 2012, 8, 3314-3321
41. Flicek, P.; Amode, M. R.; Barrell, D.; Beal, K.; Brent, S.; Chen, Y.; Clapham, P.; Coates, G.; Fairley, S.; Fitzgerald, S. Ensembl 2011 Nucleic Acids. Res. 2011, 39, 800-806
42. Nelson, M. R.; Wegmann, D.; Ehm, M. G.; Kessner, D.; Jean, P. S.; Verzilli, C.; Shen, J.; Tang, Z.; Bacanu, S. A.; Fraser, D. An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people Science 2012, 337, 100-104
43. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J. B.; Meyer, E. F.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The protein data bank Eur. J. Biochem. 2008, 80, 319-324
44. Dingerdissen, H.; Motwani, M.; Karagiannis, K.; Simonyan, V.; Mazumder, R. Proteome-wide analysis of nonsynonymous single-nucleotide variations in active sites of human proteins FEBS J. 2013, 280, 1542-1562
45. Wang, R.; Lu, Y.; Wang, S. Comparative evaluation of 11 scoring functions for molecular docking J. Med. Chem. 2003, 46, 2287-2303
46. Hou, x.; Du, J.; Zhang, J.; Du, L.; Fang, H.; Li, M. How to improve docking accuracy of AutoDock4.2: A case study using different electrostatic potentials J. Chem. Inf. Model. 2013, 53, 188-200
47. Yun, C.-H.; Boggon, T. J.; Li, Y.; Woo, M. S.; Greulich, H.; Meyerson, M.; Eck, M. J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity Cancer cell 2007, 11, 217-227
48. Balius, T. E.; Rizzo, R. C. Quantitative prediction of fold resistance for inhibitors of EGFR Biochemistry 2009, 48, 8435-8448
49. Mahfoudi, A.; Roulet, E.; Dauvois, S.; Parker, M. G.; Wahli, W. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 4206-4210
50. Rajendra, S.; Lynch, J. W.; Pierce, K. D.; French, C. R.; Barry, P. H.; Schofield, P. R. Mutation of an arginine residue in the human glycine receptor transforms β-alanine and taurine from agonists into competitive antagonists Neuron 1995, 14, 169-175
51. Turki, J.; Lorenz, J. N.; Green, S. A.; Donnelly, E. T.; Jacinto, M.; Liggett, S. B. Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 10483-10488
52. Bessis, A.-S.; Rondard, P.; Gaven, F.; Brabet, I.; Triballeau, N.; Prézeau, L.; Acher, F.; Pin, J.-P. Closure of the Venus flytrap module of mGlu8 receptor and the activation process: Insights from mutations converting antagonists into agonists Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 11097-11102
53. Dishy, V.; Landau, R.; Sofowora, G. G.; Xie, H.-G.; Smiley, R. M.; Kim, R. B.; Byrne, D. W.; Wood, A. J.; Stein, C. M. Beta2-adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo Pharmacogenetics 2004, 14, 517-522
54. Boeck, A. T.; Fry, D. L.; Sastre, A.; Lockridge, O. Naturally occurring mutation, Asp70His, in human butyrylcholinesterase Ann. Clin. Biochem. 2002, 39, 154-156
55. Masson, P.; Froment, M.; Bartels, C.; Lockridge, O. Importance of aspartate-70 in organophosphate inhibition, oxime re-activation and aging of human butyrylcholinesterase Biochem. J. 1997, 325, 53-61
56. Amberger, J.; Bocchini, C. A.; Scott, A. F.; Hamosh, A. McKusick's online Mendelian inheritance in man (OMIM®) Nucleic Acids. Res. 2009, 37, 793-796
57. Hamosh, A.; Scott, A. F.; Amberger, J. S.; Bocchini, C. A.; McKusick, V. A. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders Nucleic Acids. Res. 2005, 33, 514-517
58. O'Connor, T. P.; Crystal, R. G. Genetic medicines: Treatment strategies for hereditary disorders Nat. Rev. Genet. 2006, 7, 261-276
59. Fischer, A.; Cavazzana-Calvo, M. Gene therapy of inherited diseases Lancet 2008, 371, 2044-2047
60. Melnikova, I. Rare diseases and orphan drugs Nat. Rev. Drug Discovery 2012, 11, 267-268
61. Brinkman, R. R.; Dubé, M.-P.; Rouleau, G. A.; Orr, A. C.; Samuels, M. E. Human monogenic disorders-A source of novel drug targets Nat. Rev. Genet. 2006, 7, 249-260
62. Krengli, M.; Jereczek-Fossa, B. A.; Kaanders, J. H.; Masini, L.; Beldi, D.; Orecchia, R. What is the role of radiotherapy in the treatment of mucosal melanoma of the head and neck? Crit. Rev. Oncol. Hematol. 2008, 65, 121-128
63. Lee, J. W.; Soung, Y. H.; Kim, S. Y.; Nam, H. K.; Park, W. S.; Nam, S. W.; Kim, M. S.; Sun, D. I.; Lee, Y. S.; Jang, J. J. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck Clin. Cancer Res. 2005, 11, 2879-2882
64. Mendelsohn, J.; Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J. Clin. Oncol. 2003, 21, 2787-2799
65. Perez, C. A.; Song, H.; Raez, L. E.; Agulnik, M.; Grushko, T. A.; Dekker, A.; Stenson, K.; Blair, E. A.; Olopade, O. I.; Seiwert, T. Y. Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck Oral Oncol. 2012, 48, 887-892
66. Cohen, E. E.; Rosen, F.; Stadler, W. M.; Recant, W.; Stenson, K.; Huo, D.; Vokes, E. E. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck J. Clin. Oncol. 2003, 21, 1980-1987
67. Bonner, J. A.; Harari, P. M.; Giralt, J.; Azarnia, N.; Shin, D. M.; Cohen, R. B.; Jones, C. U.; Sur, R.; Raben, D.; Jassem, J. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N. Engl. J. Med. 2006, 354, 567-578
68. Li, Z.; Zhou, S.; Zhang, L.; Su, C.; Hang, J.; Zhao, Y.; Su, B.; Zhou, C. BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer Med. Oncol. 2011, 28, 572-577
69. Wakeling, A. E.; Guy, S. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Barker, A. J.; Gibson, K. H. ZD1839 (Iressa) an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy Cancer Res. 2002, 62, 5749-5754
70. Koizumi, F.; Shimoyama, T.; Taguchi, F.; Saijo, N.; Nishio, K. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib Int. J. Cancer 2005, 116, 36-44
71. Cheng, H.; An, S. J.; Dong, S.; Zhang, Y. F.; Zhang, X. C.; Chen, Z. H.; Su, J.; Wu, Y. L. Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib J. Hematol. Oncol. 2011, 4, 5-17